search
Back to results

Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

Primary Purpose

Langerhans Cell Histiocytosis of Bone

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Prednisone
Sponsored by
Shanghai Changzheng Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Langerhans Cell Histiocytosis of Bone focused on measuring Langerhans cell histiocytosis, Bone, Single-system, Children, Adolescents

Eligibility Criteria

2 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Pathological diagnosis of Langerhans cell histiocytosis (LCH) of bone; Single-system involvement (skeletal system); No need of surgical intervention; Must be able to swallow tablets; Signing informed consent form. Exclusion Criteria: Multi-system involvements (≥2 systems, including bone, liver, spleen, hematologic system, central nerve system); Need of surgical intervention (e.g. pathological fracture and/or spinal cord compression) Glucocorticoid allergy; Immunodeficiency; Severe infection; Insulin dependent/independent Diabetes; Having taken glucocorticoid in the past two weeks; Not capable of swallowing tablets; Without signed informed consent inform.

Sites / Locations

  • Shanghai Changzheng HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Oral prednisone

Regular observation

Arm Description

Oral prednisone, 0.5mg/kg/day, first 5 days/month, 6months

Regular observation and follow up without medication

Outcomes

Primary Outcome Measures

Progression-free survival
Any evidence proving the disease progression

Secondary Outcome Measures

Local control rate
radiological examinations of local lesion status
Pain relief
The Visual Analogue Scale (Minimum: 0; Maximum: 10 scores), is used to evaluate the degree of pain relief. The higher scores mean a worse outcome.
Adverse effect rate
side effects related to the prednisone

Full Information

First Posted
September 27, 2023
Last Updated
October 15, 2023
Sponsor
Shanghai Changzheng Hospital
Collaborators
First Affiliated Hospital of Zhejiang University, Peking University Third Hospital, National Sun Yat-sen University, Beijing Children's Hospital, Henan Cancer Hospital, Tianjin Hospital, First Affiliated Hospital, Sun Yat-Sen University, Second Hospital of Jilin University, Peking University People's Hospital, Jinling hospital Nanjing, Jiangsu, China, The First Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Southern Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT06078969
Brief Title
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Official Title
The Efficacy of Oral Prednisone in Treating Langerhans Cell Histiocytosis of Bone in Childhood and Adolescence: A Multi-center, Open-label, Randomized-controlled, Phase II Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
September 30, 2027 (Anticipated)
Study Completion Date
September 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Changzheng Hospital
Collaborators
First Affiliated Hospital of Zhejiang University, Peking University Third Hospital, National Sun Yat-sen University, Beijing Children's Hospital, Henan Cancer Hospital, Tianjin Hospital, First Affiliated Hospital, Sun Yat-Sen University, Second Hospital of Jilin University, Peking University People's Hospital, Jinling hospital Nanjing, Jiangsu, China, The First Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Southern Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Langerhans cell histiocytosis (LCH) of bone is a benign-tumor-like osteolytic lesion in childhood and adolescence, which is characterized by the aberrant activation of antigen presenting cells. Rather than the multi-system involvements of LCH, no standard or widely-accepted therapeutic regimens were established for LCH of bone. In the previous clinical practice, several LCH patients obtained remarkable pain relief after taking prednisone. Therefore, the investigators aim to conducting a multi-center, open-labelled, randomized-controlled, Phase II study to investigate the efficacy and safety of oral prednisone in treating LCH of bone in children and adolescents. The enrolled patients will be randomly recruited to the following groups: (1) Oral prednisone [Test group); (2) Regular observation [Control group].

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Langerhans Cell Histiocytosis of Bone
Keywords
Langerhans cell histiocytosis, Bone, Single-system, Children, Adolescents

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Model Description
If the diseae progression in the control group is confirmed, the patient is allowed to transferred to the test group (Oral prednisone).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
118 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Oral prednisone
Arm Type
Experimental
Arm Description
Oral prednisone, 0.5mg/kg/day, first 5 days/month, 6months
Arm Title
Regular observation
Arm Type
No Intervention
Arm Description
Regular observation and follow up without medication
Intervention Type
Drug
Intervention Name(s)
Prednisone
Intervention Description
For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
Primary Outcome Measure Information:
Title
Progression-free survival
Description
Any evidence proving the disease progression
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Local control rate
Description
radiological examinations of local lesion status
Time Frame
2 years
Title
Pain relief
Description
The Visual Analogue Scale (Minimum: 0; Maximum: 10 scores), is used to evaluate the degree of pain relief. The higher scores mean a worse outcome.
Time Frame
2 years
Title
Adverse effect rate
Description
side effects related to the prednisone
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathological diagnosis of Langerhans cell histiocytosis (LCH) of bone; Single-system involvement (skeletal system); No need of surgical intervention; Must be able to swallow tablets; Signing informed consent form. Exclusion Criteria: Multi-system involvements (≥2 systems, including bone, liver, spleen, hematologic system, central nerve system); Need of surgical intervention (e.g. pathological fracture and/or spinal cord compression) Glucocorticoid allergy; Immunodeficiency; Severe infection; Insulin dependent/independent Diabetes; Having taken glucocorticoid in the past two weeks; Not capable of swallowing tablets; Without signed informed consent inform.
Facility Information:
Facility Name
Shanghai Changzheng Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaohui He, MD;PhD
Phone
086+18221376577
Email
heshaohui1025@163.com
First Name & Middle Initial & Last Name & Degree
Chen Ye, MD
Phone
086+17621628515
Email
chenye@usst.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Time Frame
1 year
Citations:
PubMed Identifier
1636041
Citation
Stull MA, Kransdorf MJ, Devaney KO. Langerhans cell histiocytosis of bone. Radiographics. 1992 Jul;12(4):801-23. doi: 10.1148/radiographics.12.4.1636041.
Results Reference
background
PubMed Identifier
23589673
Citation
Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14. doi: 10.1182/blood-2012-09-455774. Epub 2013 Apr 15.
Results Reference
background
PubMed Identifier
36176854
Citation
Mitchell P, Ezeokoli EU, Borici N, Schleh E, Montgomery N. Treatment and Outcomes of Unifocal and Multifocal Osseous Pelvic Langerhans Cell Histiocytosis Lesions in a Pediatric Population. Cureus. 2022 Aug 27;14(8):e28470. doi: 10.7759/cureus.28470. eCollection 2022 Aug.
Results Reference
background
PubMed Identifier
22052526
Citation
Baptista AM, Camargo AF, de Camargo OP, Odone Filho V, Cassone AE. Does adjunctive chemotherapy reduce remission rates compared to cortisone alone in unifocal or multifocal histiocytosis of bone? Clin Orthop Relat Res. 2012 Mar;470(3):663-9. doi: 10.1007/s11999-011-2162-x.
Results Reference
background
PubMed Identifier
27923375
Citation
Zhong N, Xu W, Meng T, Yang X, Yan W, Xiao J. The surgical strategy for eosinophilic granuloma of the pediatric cervical spine complicated with neurologic deficit and/or spinal instability. World J Surg Oncol. 2016 Dec 7;14(1):301. doi: 10.1186/s12957-016-1063-6.
Results Reference
background
PubMed Identifier
34459688
Citation
Tang X, Gao J, Ma ZG, Guo X, Li Q, Wan Z, Sun JJ. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Ann Med. 2021 Dec;53(1):1537-1546. doi: 10.1080/07853890.2021.1966085.
Results Reference
background

Learn more about this trial

Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

We'll reach out to this number within 24 hrs